ADAP
Adaptimmune Therapeutics Plc
Halal Rating :
Last Price
$0.58
Last updated:
Market Cap
-
7D Change
-2.57%
1 Year Change
-20.14%
Company Overview
Industries
Exchange
Next Earnings Date
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapy products. The company's proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer cells. Their primary focus is on developing treatments for solid tumors.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $40.9m | $56.69m | - | $1.11m | 0.00% | 1.96% |
| June 30, 2024 | $128.23m | $60.06m | - | $526000.0 | 0.00% | 0.88% |
| March 31, 2024 | $5.68m | $54.94m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Adaptimmune Therapeutics Plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.